The Technical Analyst
BioAtla, Inc. [BCAB]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
BioAtla, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.16% $2.94
Last updated: 3 jul 2022 - 19:29
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 110.00 mill |
| EPS: | -2.85 |
| P/E: | 0.000 |
| Earnings Date: | Aug 11, 2022 |
| SharesOutstanding: | 37.41 mill |
| Avg Daily Volume: | 0.615 mill |
| RATING 2022-07-01 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/20 | 4/20 | 1/21 | 2/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$32.01 (988.66%) $29.07 |
| Date: 2022-07-03 |
| True Range Average |
|---|
|
+/- $0.288 ( +/- 9.80%) Range: 2.65 - 3.23 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-30 | Short Jay M Phd | Sell | 2 888 | Common Stock |
| 2022-06-30 | Waldron Richard A | Sell | 970 | Common Stock |
| 2022-06-30 | Vasquez Christian | Sell | 194 | Common Stock |
| 2022-06-30 | Sievers Eric | Sell | 555 | Common Stock |
| 2022-06-30 | Smith Scott Andrew | Sell | 1 791 | Common Stock |
| INSIDER POWER |
|---|
| 78.57 |
| Last 100 transactions |
| Buy: 1 068 085 | Sell: 140 491 |
Forecast:
16:00 - $2.94
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.94
Forecast 2: 16:00 - $2.94
Forecast 3: 16:00 - $2.94
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.94 (3.16% ) |
| Volume | 0.427 mill |
| Avg. Vol. | 0.615 mill |
| % of Avg. Vol | 69.37 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCAB
16 Signals | Accuracy: 18.75% | Accuracy Buy: 25.00% | Accuracy Sell: 12.50%
Avg return buy: -0.22 % | Avg return sell: 0.12 %
$1 invested is now $0.98 or -1.72% since 30-06-22
| Date | Signal | @ | Closed | % | Jun 30 - 12:50 | sell | $2.99 | N/A | Active |
|---|---|---|---|---|
| Jun 30 - 12:40 | buy | $2.99 | $2.99 @ Jun 30 - 12:50 | -0.21% |
| Jun 30 - 12:35 | sell | $2.98 | $2.99 @ Jun 30 - 12:40 | 0.55% |
| Jun 30 - 12:26 | buy | $3.00 | $2.98 @ Jun 30 - 12:35 | -0.83% |
| Jun 30 - 11:59 | sell | $2.99 | $3.00 @ Jun 30 - 12:26 | 0.50% |
| Jun 30 - 11:44 | buy | $2.98 | $2.99 @ Jun 30 - 11:59 | 0.17% |
| Jun 30 - 11:22 | sell | $2.98 | $2.98 @ Jun 30 - 11:44 | 0.17% |
| Jun 30 - 11:09 | buy | $2.97 | $2.98 @ Jun 30 - 11:22 | 0.17% |
| Jun 30 - 11:03 | sell | $2.96 | $2.97 @ Jun 30 - 11:09 | 0.34% |
| Jun 30 - 10:52 | buy | $2.96 | $2.96 @ Jun 30 - 11:03 | 0.00% |
BCAB
Latest Press Releases
2022-03-01 06:00:00 - Press Release
Bioatla Announces Fourth Quarter And Full Year 2021 Financial Results
San diego, march 1, 2022 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announces its financial results for the fourth quarter and full year december 31, 2021, and provides an update on product pipeline developments. "bioatla made significant progress in 2021 by advancing the potentially registration-enabling phase 2 clinical trials for our two lead cab product candidates as well as our other preclinical and pipeline programs.
2022-01-10 16:05:00 - Press Release
Bioatla Announces Clinical Collaboration With Bristol Myers Squibb To Study Mecbotamab Vedotin (ba3011) And Ozuriftamab Vedotin (ba3021) In Combination With Opdivo® (nivolumab) For Treatment Of Solid Tumors
San diego, jan. 10, 2022 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announced that it has entered into a clinical collaboration with bristol myers squibb (nyse: bmy) to investigate bioatla's two lead cab-adc candidates, ba3011 and ba3021, in combination with bristol myers squibb's anti-pd-1 therapy opdivo® (nivolumab). under the terms of the agreement, bioatla and bristol myers squibb will collaborate on clinical trials of separate combination therapies using two of bioatla's conditionally active biologic antibody drug conjugates, ba3011 and ba3021, each in combination with opdvio.
2021-11-15 17:09:00 - Press Release
Bioatla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update
San diego, nov. 15, 2021 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announced financial results for the third quarter of 2021 and provided an update on its clinical progress and business. "bioatla continues to advance the progress of the potentially registration-enabling phase 2 clinical trials for our two lead cab product candidates as well as our other preclinical and pipeline programs.
2021-09-29 08:03:00 - Press Release
Bioatla Announces Private Placement Of 2.7 Million Shares
San diego, sept. 29, 2021 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of institutional investors in connection with a private placement of its common stock.
2021-08-13 17:54:00 - Press Release
Bioatla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
San diego, aug. 13, 2021 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an update on its business. "bioatla is advancing potentially registration-enabling phase 2 clinical trials for our two lead cab product candidates.
Latest News
2022-06-01 16:05:00 - GlobeNewsWire
BioAtla to Participate in 2022 Jefferies Global Healthcare Conference
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder, and Scott Smith, President, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY June 8-10, 2022.
2022-05-07 15:06:04 - Seeking Alpha
BioAtla, Inc. (BCAB) CEO Jay Short on Q1 2022 Results - Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - President Philippe Martin - Chief of Clinical Development and Operations Sheri Lydick - Senior Vice President, Commercial Strategy Richard Waldron - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Tiago Fauth - Credit Suisse Kelly Shi - Jefferies Kaveri Pohlman - BTIG Tony Butler - ROTH Capital Arthur He - H.C. Wainwright Operator Good day, and thank you for standing by.
2022-04-08 08:00:00 - GlobeNewsWire
BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022
SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial results for the quarter ended March 31, 2022, and provide an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071).
2021-09-29 08:03:00 - PRNewsWire
BioAtla Announces Private Placement of 2.7 Million Shares
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of institutional investors in connection with a private placement of its common stock.
2021-08-13 17:54:00 - PRNewsWire
BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update
SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the second quarter of 2021 and provided an update on its business. "BioAtla is advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates.
2021-05-12 18:26:00 - PRNewsWire
BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update
SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the first quarter of 2021 and provided an update on its business. "BioAtla is rapidly advancing potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates.
2021-02-07 07:29:34 - Seeking Alpha
BioAtla: Intriguing Science, New IPO, A Name To Watch
BioAtla is developing selectively-targeting antibodies based on very interesting science. However, it is a new IPO, and current prices and cash reserves are not conducive to investment.
2020-12-26 13:53:45 - Benzinga
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.
2020-12-18 16:00:00 - PRNewsWire
BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial...
2020-12-15 19:59:00 - PRNewsWire
BioAtla Announces Pricing of Initial Public Offering
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial...